Fig. 1 · Structure

Documents & Downloads

Propofol

Cat. No. A18293 CAS 2078-54-8
Propofol is a hypnotic alkylphenol derivative. Propofol is a General Anesthetic. Propofol is a short-acting medication that results in a decreased level of consciousness and lack of memory for events. Formulated for intravenous induction of sedation and hypnosis during anesthesia, propofol facilitates inhibitory neurotransmission mediated by gamma-aminobutyric acid (GABA).

In Stock

Publications for Propofol

2 publications citing this product

  1. Daphne Chun-Che Chien, .et al. , Sci Transl Med, 2024, May 8;16(746):eadk8198 PMID: 38718132
  2. Chenghao Jin, .et al. , Immun Inflamm Dis, 2023, Aug;11(8):e952 PMID: 37647434

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Propofol potentiated GABA-evoked currents and directly activated recombinant α1β2γ2 GABA_A receptors. β2(N265M) and β2(M286W) substitutions reduced both effects, supporting a subunit-dependent mechanism. These functional data do not establish direct binding affinity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Human Endogenous Metabolite  

Cellular Effect

Cell Line Activity Value Description Reference
A549 EC50 9.55 mM Cytotoxicity against human A549 cells after 24 hrs by MTT assay [PMID: 30318437]
L929 EC50 4.73 mM Cytotoxicity against mouse L929 cells after 24 hrs by MTT assay [PMID: 30318437]
Oocyte EC50 11.2 μM Effective concentration against GABA-evoked chloride currents mediated by human Gamma-aminobutyric acid GABA-A receptor alpha2-beta2-gamma2L expressed in Xenopus oocytes [PMID: 15801854]
Oocyte EC50 5.2 μM Agonist activity at human alpha1beta2gamma2L GABAA receptor expressed in Xenopus oocytes assessed as potentiation of GABA-induced current response by two-electrode voltage clamp electrophysiology assay [PMID: 22029276]
Oocyte EC50 50 μM Agonist activity at human alpha1beta2gamma2L GABAA receptor expressed in Xenopus oocytes assessed as potentiation of channel current response by two-electrode voltage clamp electrophysiology assay [PMID: 22029276]

Propofol Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Propofol from 2 published references.

Propofol In Vitro Studies

In HEK293 cells, 10 μM propofol increased the wild-type receptor GABA current by 100.7 ± 17% (mean ± standard error; n = 16). Direct activation at 50 μM reached 20 ± 7% of the maximal GABA current (n = 12). These are functional responses at test concentrations, rather than IC50 values. [1]

Potentiation and direct activation of recombinant GABA_A receptors

Cell-based study · HEK293 cells expressing rat α1β2γ2short GABA_A receptors, wild type or β2(N265M)/β2(M286W) [1]

Propofol potentiated submaximal GABA currents and directly activated receptors at a higher concentration. Both β2 mutations reduced these responses. Baseline GABA sensitivity also changed, so mutant comparisons used receptor-specific EC15 GABA.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Increase in GABA-induced chloride currentPotentiation (%) WT: 100.7 ± 17% (n = 16); N265M: 43.5 ± 10.1% (n = 10); M286W: 48.4 ± 13.2% (n = 16). Both mutant responses smaller than WT, p < 0.05. Mean ± standard error.[1]
Propofol-evoked current relative to separately determined maximal GABA currentPercentage of maximal GABA current WT: 20 ± 7% (n = 12); N265M: 0.7% ± 0.3% (n = 17); M286W: 2.0 ± 0.8% (n = 10). Both mutant responses smaller than WT, p < 0.05. Mean ± standard error.[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM for potentiation; 50 μM for direct activation
Exposure duration
5-second applications; GABA applications every 1.5 min
Method
Whole-cell patch clamp at −60 mV, room temperature
Vehicle
DMSO ≤0.1%; reported to have no effect on GABA responses
Co-treatment
For potentiation: GABA 3 μM (WT), 8 μM (N265M), 1 μM (M286W); direct activation without GABA
Reported limits
Propofol from Aldrich; lot/purity not given in acquired material description.
Methods and source locations

Compound reported in the paper: Propofol; Compound label in the paper: propofol

Research compound evidence; supplier and formulation are specific to the study.

Results: Propofol under modulation and direct activation; Figures 1, 2 and 4; Methods; Solutions and drugs

Increase in GABA-induced chloride current: Matched approximate EC15 GABA for each receptor; Student’s t-test — Results modulation/Propofol; Figure 2a,b

Propofol-evoked current relative to separately determined maximal GABA current: 50 μM propofol without GABA; Student’s t-test — Results direct activation/Propofol; Figure 4a,b

Propofol In Vivo Studies

At 30 mg/kg intravenously, propofol produced shorter loss of righting reflex and no loss of hindlimb withdrawal reflex in β3(N265M) mice compared with wild-type mice on two congenic backgrounds. The result supports β3-containing GABA_A receptor involvement in these behavioral endpoints. [2]

In a separate passive-avoidance experiment, propofol impaired next-day retrieval in both wild-type and β3(N265M) mice, without a significant genotype effect (p = 0.067). β3-dependent reflex effects therefore do not account for every measured anesthetic action. [2]

Genetic-background validation of propofol reflex effects

Animal study · Wild-type and β3(N265M) mice on congenic C57BL/6J and 129X1/SvJ backgrounds; 4–7 months old [2]

Following 30 mg/kg intravenous propofol, mutant mice showed shorter loss of righting reflex and no loss of hindlimb withdrawal reflex in both backgrounds. These are behavioral proxies and do not define all components of anesthesia.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Duration of loss of righting reflex (LORR) and hindlimb withdrawal reflex (LHWR)Genotype comparison LORR reduced and LHWR absent in β3(N265M) mice relative to wild type in both genetic backgrounds; Figure 4 marks p < 0.001 for each propofol comparison; n = 10 as caption reports. Results expressed as mean ± SEM. No exact bar heights extracted.[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
One administration per behavioral test
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Propofol dose series and genotype controls
30 mg/kg
Corresponding wild-type mice in each congenic backgroundMutants: reduced LORR and absent LHWR versus wild type in both backgrounds.[2]
Propofol dose series and genotype controls
Model: Wild-type and β3(N265M) mice on congenic C57BL/6J and 129X1/SvJ backgrounds; 4–7 months old
Reported limits: Reflex-specific vehicle, injection frequency, observation schedule and sex not explicitly provided in the acquired reflex description; no telemetry vehicle imported.
Methods and source locations

Compound reported in the paper: Propofol; Compound label in the paper: propofol

Research compound evidence; supplier and formulation are specific to the study.

Results: genetic background effects; Figure 4A–D; Methods Animals and statistical analysis

Duration of loss of righting reflex (LORR) and hindlimb withdrawal reflex (LHWR): Unpaired Student’s t-test — Figure 4A–D and caption; Methods statistical analysis

Propofol dose series and genotype controls · Results: genetic background effects; Figure 4A–D; Methods Animals and statistical analysis

Propofol amnesia persists in β3(N265M) mice

Animal study · Wild-type and β3(N265M) mice on congenic 129X1/SvJ background; 6–8 weeks old [2]

Propofol reduced next-day passive-avoidance retrieval latency in both genotypes. No significant genotype effect was detected, limiting attribution of propofol amnesia to β3-containing receptors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Latency to re-enter the dark compartment at retrievalRepeated measures ANOVA Drug effect: F(4,112) = 4.997, p < 0.001; genotype effect: F(1,112) = 3.413, p = 0.067. Caption n = 15. Retrieval latency decreased similarly across genotypes; no exact bar values extracted.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
One administration per behavioral test
Treatment course
20 min before training; retrieval at 24 h
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Propofol dose series and genotype controls
0 (vehicle), 25, 50, 75 and 100 mg/kg
Corresponding wild-type genotype; vehicle-treated groups included in passive avoidanceDose-dependent impairment of retrieval in both genotypes; genotype effect not significant.[2]
Propofol dose series and genotype controls
Model: Wild-type and β3(N265M) mice on congenic 129X1/SvJ background; 6–8 weeks old
Reported limits: Vehicle identity for this behavioral experiment and sex not explicitly stated in the acquired task-specific description; do not infer from telemetry methods.
Methods and source locations

Compound reported in the paper: Propofol; Compound label in the paper: propofol

Research compound evidence; supplier and formulation are specific to the study.

Results: Propofol induces anterograde amnesia; Figure 5; Methods passive avoidance, Animals and statistics

Latency to re-enter the dark compartment at retrieval: Repeated measures ANOVA followed by Bonferroni post hoc test; mean ± SEM per Methods — Results anterograde amnesia; Figure 5 and caption

Propofol dose series and genotype controls · Results: Propofol induces anterograde amnesia; Figure 5; Methods passive avoidance, Animals and statistics

Specifications

Manufacturer Adooq Bioscience
CAS Number 2078-54-8
Formula C12H18O
Molecular Weight 178.27
Synonyms 2,6-DIISOPROPYLPHENOL; Diprivan; Disoprofol; Disoprivan; Fresenius Brand of Propofol; Fresenius Kabi Brand of Propofol; Fresofol; ICI 35,868; ICI 35868
SMILES
CC(C)C1=C(C(=CC=C1)C(C)C)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Propofol Research References

  1. [1] Roberta Siegwart, Karin Krähenbühl, Sachar Lambert, et al. Mutational analysis of molecular requirements for the actions of general anaesthetics at the γ-aminobutyric acidA receptor subtype, α1β2γ2 BMC Pharmacology (2003). PMID: 14613517 DOI: 10.1186/1471-2210-3-13 Source material
  2. [2] Anja Zeller, Margarete Arras, Rachel Jurd, et al. Mapping the contribution of β3-containing GABAA receptors to volatile and intravenous general anesthetic actions BMC Pharmacology (2007). PMID: 17319964 DOI: 10.1186/1471-2210-7-2 Source material

Publications

2 publications citing this product

  1. Daphne Chun-Che Chien, .et al. , Sci Transl Med, 2024, May 8;16(746):eadk8198 PMID: 38718132
  2. Chenghao Jin, .et al. , Immun Inflamm Dis, 2023, Aug;11(8):e952 PMID: 37647434

Added to your cart

View Cart Checkout
Loading...